The "E" in cost-effectiveness analyses: A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence

Annals of the American Thoracic Society

Volumn 11, Issue SUPPL. 2, 2014, Pages

  Campbell, Jonathan D ^a   McQueen, R Brett ^a   Briggs, Andrew ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Asthma; Cost effectiveness; Health technology assessment; Real world

Indexed keywords

OMALIZUMAB;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; LICENCE; MEDICAL DECISION MAKING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; OBSERVATIONAL STUDY AS TOPIC; PRAGMATIC CLINICAL TRIALS AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 84898733916     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201309-295RM     Document Type: Conference Paper

References (45)

1. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008;372:2152-2161.
2. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol 2009;62:499-505.
3. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967;20:637-648.
4. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ 2009;180:E47-E57.
5. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464-475.
6. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:a2390.
7. Drummond M, Sculpher M, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
8. Gold M, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
9. Drummond MF. The use of health economic information by reimbursement authorities. Rheumatology (Oxford) 2003;42:iii60-iii63. (Pubitemid 37407015)
10. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC; Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-1177. (Pubitemid 26329746)
11. Siegel JE, Weinstein MC, Russell LB, Gold MR; Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276:1339-1341. (Pubitemid 26346934)
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258. (Pubitemid 26337709)
13. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887 -1892.
14. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005;365:82-93. (Pubitemid 40082150)
15. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005;8:521-533. (Pubitemid 41727304)
16. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-227. (Pubitemid 27296586)
17. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices-Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
18. Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics 2008;26:131-148.
19. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood) 2010;29:1818-1825.
20. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ 2006;15:677-687. (Pubitemid 44057239)
21. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 2007;10:326-335. (Pubitemid 47481104)
22. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, Juniper EF, Ayres JG, Kemp L, Blyth A, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-1707.
23. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-844. (Pubitemid 39346477)
24. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, Weiss S, Zheng B, Johnson C, Wenzel S; TENOR Study Group. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32-39. (Pubitemid 38113629)
25. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2012 (update) [accessed 2013 Aug 12]. Available from: http://www.ginasthma.org/documents/4
26. European Medicines Agency. Omalizumab label [accessed 2013 Aug 12]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--- Scienti fic-Discussion/human/000606/WC500057295.pdf
27. US Food and Drug Administration. Omalizumab label. [accessed 2013 Aug 12]. Available from: http://www.gene.com/download/pdf/xolair-prescribing.pdf
28. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-308. (Pubitemid 40293345)
29. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149-153. (Pubitemid 46090296)
30. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65:1141-1148.
31. Dewilde S, Turk F, Tambour M, Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-1776. (Pubitemid 44449233)
32. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265-269. (Pubitemid 39119022)
33. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120:1146-1152. (Pubitemid 350029901)
34. van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Media Econ 2013;16:342-348.
35. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008;63:670-684. (Pubitemid 351591863)
36. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101:1483-1492. (Pubitemid 46850589)
37. Carranza Rosenzweig JR, Edwards L, Lincourt W, Dorinsky P, ZuWallack RL. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 2004;98:1157-1165. (Pubitemid 39497216)
38. Martin TG, Elenbaas RM, Pingleton SH. Failure of peak expiratory flow rate to predict hospital admission in acute asthma. Ann Emerg Med 1982;11:466-470. (Pubitemid 13235276)
39. Teeter JG, Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 1998;113:272-277. (Pubitemid 28109997)
40. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-316. (Pubitemid 40293346)
41. Braunstahl GJ, Leo J, Thirlwell J, Peachey G, Maykut R. Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Curr Med Res Opin 2011;27:761-767.
42. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009;103:1633-1642.
43. Löwhagen O, Ekström L, Holmberg S, Wennerblom B, Rosenfeldt M. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243-247. (Pubitemid 28014667)
44. Watson L, Turk F, James P, Holgate ST. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med 2007;101:1659-1664. (Pubitemid 46947879)
45. Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indicies from non-preference based condition-specific instruments: Converting AQLQ into EQ-5D indices. Sheffield, UK: The University of Sheffield, School of Health and Related Research, Sheffield Health Economics Group Discussion Paper Series 02/1, May 2002.